308 related articles for article (PubMed ID: 24158513)
1. Globotriaosylceramide induces lysosomal degradation of endothelial KCa3.1 in fabry disease.
Choi S; Kim JA; Na HY; Cho SE; Park S; Jung SC; Suh SH
Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):81-9. PubMed ID: 24158513
[TBL] [Abstract][Full Text] [Related]
2. Globotriaosylceramide leads to K(Ca)3.1 channel dysfunction: a new insight into endothelial dysfunction in Fabry disease.
Park S; Kim JA; Joo KY; Choi S; Choi EN; Shin JA; Han KH; Jung SC; Suh SH
Cardiovasc Res; 2011 Feb; 89(2):290-9. PubMed ID: 20971723
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis and Molecular Mechanisms of Anderson-Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies.
Tuttolomondo A; Simonetta I; Riolo R; Todaro F; Di Chiara T; Miceli S; Pinto A
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576250
[TBL] [Abstract][Full Text] [Related]
4. Globotriaosylceramide induces endothelial dysfunction in fabry disease.
Satoh K
Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):2-4. PubMed ID: 24335674
[No Abstract] [Full Text] [Related]
5. An in vitro model of Fabry disease.
Shu L; Murphy HS; Cooling L; Shayman JA
J Am Soc Nephrol; 2005 Sep; 16(9):2636-45. PubMed ID: 16033856
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis for globotriaosylceramide regulation and enzyme uptake in immortalized aortic endothelial cells from Fabry mice.
Meng XL; Day TS; McNeill N; Ashcraft P; Frischmuth T; Cheng SH; Liu ZP; Shen JS; Schiffmann R
J Inherit Metab Dis; 2016 May; 39(3):447-455. PubMed ID: 26960552
[TBL] [Abstract][Full Text] [Related]
7. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.
Sueoka H; Aoki M; Tsukimura T; Togawa T; Sakuraba H
PLoS One; 2015; 10(12):e0144958. PubMed ID: 26661087
[TBL] [Abstract][Full Text] [Related]
8. Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect.
Park JL; Whitesall SE; D'Alecy LG; Shu L; Shayman JA
Clin Exp Pharmacol Physiol; 2008 Oct; 35(10):1156-63. PubMed ID: 18565198
[TBL] [Abstract][Full Text] [Related]
9. Enzyme replacement therapy partially prevents invariant Natural Killer T cell deficiency in the Fabry disease mouse model.
Macedo MF; Quinta R; Pereira CS; Sa Miranda MC
Mol Genet Metab; 2012 May; 106(1):83-91. PubMed ID: 22425450
[TBL] [Abstract][Full Text] [Related]
10. Differential involvement of COX1 and COX2 in the vasculopathy associated with the alpha-galactosidase A-knockout mouse.
Park JL; Shu L; Shayman JA
Am J Physiol Heart Circ Physiol; 2009 Apr; 296(4):H1133-40. PubMed ID: 19202000
[TBL] [Abstract][Full Text] [Related]
11. Lyso-globotriaosylceramide downregulates KCa3.1 channel expression to inhibit collagen synthesis in fibroblasts.
Choi JY; Shin MY; Suh SH; Park S
Biochem Biophys Res Commun; 2015 Dec; 468(4):883-8. PubMed ID: 26592662
[TBL] [Abstract][Full Text] [Related]
12. The endothelium at the brink of calamity in storage disease: more than just overloaded with junk?
de Wit C
Cardiovasc Res; 2011 Feb; 89(2):258-9. PubMed ID: 21148146
[No Abstract] [Full Text] [Related]
13. NADPH oxidase 2-derived superoxide downregulates endothelial KCa3.1 in preeclampsia.
Choi S; Kim JA; Na HY; Kim JE; Park S; Han KH; Kim YJ; Suh SH
Free Radic Biol Med; 2013 Apr; 57():10-21. PubMed ID: 23261940
[TBL] [Abstract][Full Text] [Related]
14. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells.
Do HS; Park SW; Im I; Seo D; Yoo HW; Go H; Kim YH; Koh GY; Lee BH; Han YM
EBioMedicine; 2020 Feb; 52():102633. PubMed ID: 31981984
[TBL] [Abstract][Full Text] [Related]
15. Cardiac manifestations of Fabry disease in G3Stg/GlaKO and GlaKO mouse models-Translation to Fabry disease patients.
Kugadas A; Artoni P; Ruangsiriluk W; Zhao M; Boukharov N; Islam R; Volfson D; Derakhchan K
PLoS One; 2024; 19(5):e0304415. PubMed ID: 38820517
[TBL] [Abstract][Full Text] [Related]
16. Dissociation of globotriaosylceramide and impaired endothelial function in α-galactosidase-A deficient EA.hy926 cells.
Kaissarian N; Kang J; Shu L; Ferraz MJ; Aerts JM; Shayman JA
Mol Genet Metab; 2018 Dec; 125(4):338-344. PubMed ID: 30413389
[TBL] [Abstract][Full Text] [Related]
17. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder.
Yam GH; Zuber C; Roth J
FASEB J; 2005 Jan; 19(1):12-8. PubMed ID: 15629890
[TBL] [Abstract][Full Text] [Related]
18. Increased globotriaosylceramide levels in a transgenic mouse expressing human alpha1,4-galactosyltransferase and a mouse model for treating Fabry disease.
Shiozuka C; Taguchi A; Matsuda J; Noguchi Y; Kunieda T; Uchio-Yamada K; Yoshioka H; Hamanaka R; Yano S; Yokoyama S; Mannen K; Kulkarni AB; Furukawa K; Ishii S
J Biochem; 2011 Feb; 149(2):161-70. PubMed ID: 20961863
[TBL] [Abstract][Full Text] [Related]
19. Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates.
Zhu X; Yin L; Theisen M; Zhuo J; Siddiqui S; Levy B; Presnyak V; Frassetto A; Milton J; Salerno T; Benenato KE; Milano J; Lynn A; Sabnis S; Burke K; Besin G; Lukacs CM; Guey LT; Finn PF; Martini PGV
Am J Hum Genet; 2019 Apr; 104(4):625-637. PubMed ID: 30879639
[TBL] [Abstract][Full Text] [Related]
20. Endothelial nitric oxide synthase uncoupling and microvascular dysfunction in the mesentery of mice deficient in α-galactosidase A.
Kang JJ; Shu L; Park JL; Shayman JA; Bodary PF
Am J Physiol Gastrointest Liver Physiol; 2014 Jan; 306(2):G140-6. PubMed ID: 24232002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
